A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo

Author(s): Yahong Wu, Wenjie Zhai, Meng Sun, Zhe Zou, Xiuman Zhou, Guodong Li, Zhongyi Yan, Yuanming Qi*, Yanfeng Gao*

Journal Name: Protein & Peptide Letters

Volume 24 , Issue 6 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.

Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66.

Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay.

Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo.

Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.

Keywords: Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 08 August, 2017
Page: [573 - 580]
Pages: 8
DOI: 10.2174/0929866524666170419152700
Price: $65

Article Metrics

PDF: 29